Skip to content

Semaglutide

Also called Ozempic, Wegovy, Rybelsus.

By Dr Chad Okay3 min read

Semaglutide is a synthetic version of the gut hormone GLP-1, made by Novo Nordisk. It is the active ingredient in Ozempic (for type 2 diabetes), Wegovy (for weight management), and Rybelsus (oral tablet for diabetes). It mimics natural GLP-1 but lasts about a week per dose instead of two minutes, which is why it is dosed weekly.

What semaglutide does in the body

Semaglutide attaches to the GLP-1 receptor on cells in the pancreas, stomach, intestines and brain. The activation triggers four main effects: insulin release in response to glucose, slowed gastric emptying, reduced appetite signalling, and lower glucagon (the hormone that raises blood sugar). The combined result is steadier blood sugar and less calorie intake, which is why the drug is approved for both diabetes and obesity.

The three brands

  • Ozempic. Once-weekly subcutaneous injection. Licensed in the UK for type 2 diabetes. Doses range from 0.25 mg to 2 mg.
  • Wegovy. Once-weekly subcutaneous injection. Licensed in the UK for chronic weight management in adults with BMI over 30 (or over 27 with weight-related comorbidity). Doses titrate to 2.4 mg.
  • Rybelsus. Daily oral tablet. Licensed in the UK for type 2 diabetes. Doses range from 3 mg to 14 mg.

How weight loss compares to other drugs

In the STEP-1 trial of Wegovy at 2.4 mg, participants lost an average of 14.9% of starting body weight over 68 weeks. Tirzepatide (Mounjaro) at the highest dose produced 22.5% in the SURMOUNT-1 trial. Older GLP-1 agonists like liraglutide produced 5 to 8%. Semaglutide sits in the middle of the modern GLP-1 class on weight loss but has the longest real-world track record.

Common side effects

  • Nausea, particularly in the first weeks of each dose increase. Affects 30 to 40% of users at higher doses.
  • Constipation. Affects roughly 1 in 5 to 1 in 4 users at full dose (around 24% on Wegovy at 2.4 mg in STEP-1; lower at lower doses).
  • Heartburn and reflux, related to slower stomach emptying.
  • Sulphur burps, often from food sitting longer in the stomach.
  • Fatigue, often related to lower calorie intake rather than the drug itself.
  • Hair shedding (telogen effluvium), usually a knock-on effect of rapid weight loss rather than a direct drug effect.

How it is taken in the UK

All three brands are prescription-only in the UK. Wegovy is available privately through registered pharmacies and via the NHS in specialist weight-management services with strict eligibility. Ozempic is on the NHS for type 2 diabetes. Doses titrate up over weeks to manage side effects. Stopping the drug typically returns appetite signalling to baseline, and weight regain is common unless eating habits and lean muscle mass have been protected.

If something feels wrong

This entry is reference information, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.

Common questions

Both contain semaglutide. Ozempic is licensed for type 2 diabetes and goes up to 2 mg per week. Wegovy is licensed for weight management and goes up to 2.4 mg per week. Wegovy uses a different injector pen and dose ladder. They are not interchangeable for licensing purposes.

Built for this.

Suna is a wearable designed to help you see your own everyday patterns, without keeping a diary. Reservations open.

Sources

  1. 1Wegovy 2.4 mg SmPC (indication, dose titration to 2.4 mg)electronic Medicines Compendium (emc)
  2. 2Ozempic 2 mg SmPC (type 2 diabetes, 0.25-2 mg weekly)electronic Medicines Compendium (emc)
  3. 3Rybelsus 3 mg SmPC (oral, 3-7-14 mg daily, type 2 diabetes)electronic Medicines Compendium (emc)
  4. 4Wegovy (semaglutide) US prescribing information (half-life ~1 week; nausea 44%, constipation 24%, vomiting 24%, diarrhea 30%)DailyMed (NIH/NLM)
  5. 5STEP 1 trial: once-weekly semaglutide 2.4 mg, 14.9% weight loss at 68 weeks (Wilding 2021)NEJM (PMID 33567185)
  6. 6SURMOUNT-1: tirzepatide once weekly for obesity (Jastreboff 2022) - NEJM primary estimand 20.9% at 15 mgNEJM (PMID 35658024)
  7. 7Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
  8. 8GI tolerability of once-weekly semaglutide 2.4 mg (pooled STEP 1-3: nausea 43.9%, constipation 24.2%)Diabetes Obes Metab (PMID 34514682)
  9. 9SCALE Obesity and Prediabetes: A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management, Pi-Sunyer et al, 2015 (~8% at 56 weeks)NEJM (PubMed)
  10. 10MHRA: warning against buying unlicensed/fake weight loss pens without a prescriptionMHRA (GOV.UK)
Written by Dr Chad Okay. Contributor: Dr Parisah Hussain, MBChB, BSc (Hons), DRCOG, MRCGP. Last updated . From Digests.

Related reading

All Digests

About Digests

Digests explains how the body works in general, everyday terms. It is not medical advice. It is not a substitute for someone who can examine you and knows your history, and we do not tell you what dose of any medicine to take.

Where we describe how something is checked or looked after, we follow UK guidance from NICE and the NHS, so the tests and routes where you live may differ. The same concerns are worth taking to your own doctor.

Some articles explain approaches that researchers have studied, including gut-directed hypnotherapy. Explaining an approach is education, not an offer of it: Suna does not provide hypnotherapy or any medical or psychological treatment.

Suna Health is building a wearable wellness device for gut health and offers a gut-directed relaxation app, and you will see both advertised alongside these pages. That commercial interest does not decide what the content says.

If you think we have got something wrong, tell us at digests@suna.health. It goes to the editor. Full terms, including our liability position, are at suna.health/terms.

The wearable for gut health and nutrition. Built by a passionate team, grounded in peer-reviewed research.

Suna

Suna is a wellness device, not a medical or diagnostic device. It does not diagnose, treat, cure, or prevent any disease. The Suna app offers a five-week gut-directed relaxation program for general wellbeing. The program is a self-guided wellness practice: it is not medical care, not psychological treatment, and not hypnotherapy, and it is not a substitute for care from a qualified practitioner. Information provided is general wellness information, not medical advice. Always consult a qualified healthcare professional about any health concern.

Suna Health US, Inc., 2810 N Church St STE 90849, Wilmington, DE 19802

© 2026 Suna Health.